Fingeraftryk
Dyk ned i forskningsemnerne om 'Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months'. Sammen danner de et unikt fingeraftryk.- Sorter
- Vægt
- Alfabetisk
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months
Precise 3 Study Investigators